Educational resource · United States
A clear path to legitimate peptide education — and licensed care, when it’s connected.
Learn which peptide medicines are FDA-approved, what the October 2026 HHS interim compounding policy does and does not allow, and how to prepare for a visit with a licensed U.S. clinician. Peptide Wellness Partners does not prescribe, dispense, or sell medications.
What Peptide Wellness Partners is
- A plain-language directory of commonly discussed peptides and their U.S. regulatory status.
- A guide to licensed clinicians and licensed pharmacies — the only lawful path for prescription peptides.
- A waitlist for updates when provider access or membership is actually configured.
- Tools to help you verify licenses and spot gray-market red flags.
What it is not
- Not a pharmacy, prescriber, or marketplace that sells peptides.
- Not an AI doctor. Software cannot legally prescribe or replace a licensed clinician.
- Not a source of dosing instructions or guaranteed results.
- Not an endorsement of any clinic, pharmacy, or compounded product.
Start here
Peptide directory
Search FDA-approved products, the six peptides named in the October 2026 HHS policy, and substances with no clear compounding path.
Licensed providers
When a telehealth partner is configured, you’ll continue to their intake. Until then, you can join the waitlist or use official license lookups.
Policy, plainly
The HHS notice is not FDA approval. It is temporary federal enforcement discretion for six peptides, with conditions, while formal rulemaking continues.
Join the waitlist
Get a note when licensed-provider access or membership is actually available. This form collects only contact details — no medical history.
Peptide directory
Status notes are educational summaries of publicly available U.S. information as of November 2026. They are not directions for use, dosing advice, or a promise that a clinician or pharmacy can provide a given substance in your state.
No peptides match that search.
Saved peptides
This list stays in your browser only. It is a personal reference, not a treatment plan or a cart.
Nothing saved yet. Open the directory and tap Save.
Talk to a licensed provider
Legitimate access requires a real evaluation by a clinician licensed in your state and, if a prescription is written, filling by a state-licensed pharmacy. Peptide Wellness Partners does not employ physicians and does not write prescriptions.
Before you continue
Use this as a prep list. It is not a medical intake, and answers stay on this device unless you later share them with a clinician.
Questions to ask a clinician or clinic
- Are you licensed in my state?
- Do you require a history, exam, or labs before prescribing?
- Which pharmacy would fill the prescription, and is it licensed to ship to my state?
- If a compounded peptide is discussed, is it a single-ingredient product that meets current federal and state rules?
- What follow-up and monitoring do you require?
Red flags
- No medical evaluation required
- Guaranteed results or pressure to buy large quantities
- The clinic will not name the pharmacy
- “Research only” products offered for personal use
- Unverifiable or overseas finished product for human use
Look up licenses yourself
These are official or widely used public tools, not a Peptide Wellness Partners provider network.
NPI / NPPES registry Texas Medical Board lookup State boards of pharmacy (NABP) NABP Safe.Pharmacy
How legitimate access works
This is the intended alternative to unregulated research-chemical websites.
Medical evaluation
A clinician (MD, DO, NP, or PA) licensed in your state reviews your history and may order labs. This can be in person or via telehealth that meets your state’s rules, including a valid patient–provider relationship.
Prescription decision
Only the clinician decides whether a prescription is appropriate. An app, chatbot, or questionnaire cannot legally make that decision.
Pharmacy filling or compounding
FDA-approved products are filled at licensed pharmacies. For certain unapproved peptides, a state-licensed 503A pharmacy may compound a patient-specific product only when federal and state rules allow it — including, for six named peptides, the conditions in the October 2026 HHS interim policy.
Dispensing and follow-up
Medication is labeled and, where state law allows, shipped to you. Responsible care includes monitoring and a way to reach the prescriber.
Policy notes
A short briefing on the October 30, 2026 HHS notice, and why it is not the same thing as FDA approval. Always read the official documents.
October 2026 HHS interim policy — at a glance
- Notice: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, published October 30, 2026, 91 FR 68526, Docket No. HHS-OASH-2026-0496.
- Named peptides: BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon (Appendix A of the policy).
- What it does: HHS states it does not intend to take federal enforcement action against a state-licensed pharmacy, federal facility, or licensed physician compounding under section 503A using those substances, if the policy’s conditions are met.
- What it does not do: It does not FDA-approve these peptides, add them to the formal 503A bulks list, apply to 503B outsourcing facilities, or authorize research-chemical or supplement sales for human use.
- Comments: The Federal Register notice said written comments would be accepted until two weeks after publication (November 13, 2026).
- Duration: Described as interim while 503A bulks-list rulemaking continues. HHS may revisit the policy if safety or quality issues arise.
Context from 2023–2024
In September 2023, FDA placed several peptide bulk substances, including BPC-157, in Category 2 of its interim 503A bulks policy because of significant safety concerns identified during review. Category 2 substances were not within FDA’s enforcement-discretion policy for compounding from bulk. Some later nominations were withdrawn and Category 2 placements changed; withdrawal is not the same as clearance for compounding. The 2026 HHS notice is a later, separate, conditional federal enforcement-discretion policy — not a finding that these products are safe or effective.
Texas notes
Federal enforcement discretion does not override Texas law. Pharmacies serving Texas patients generally need appropriate Texas licensure or nonresident authorization. Prescribers must be licensed in Texas (or the applicable professional board) and meet Texas telehealth and standard-of-care rules, including a valid patient–provider relationship. Confirm current rules with the boards.
Verify sources
Use official boards and recognized pharmacy-safety tools. A polished website is not proof of licensure.
State board of pharmacy
The authoritative source for whether a pharmacy is licensed in a state, including nonresident licenses for shipping.
NABP Safe.Pharmacy
Check whether an online pharmacy website has been reviewed by the National Association of Boards of Pharmacy.
Verification checklist
Pricing
These tiers are placeholders so the site can show a membership structure. Prices and checkout are not active. Configure them in the site settings before any public offer.
FAQ & compliance
Are the HHS-policy peptides FDA-approved?
No. The October 2026 HHS policy is enforcement discretion only. It does not approve the peptides or add them to the formal 503A bulks list. They remain unapproved drugs.
Can I buy research peptides online for personal use?
Selling unapproved peptides for human use is illegal regardless of “research only” labeling. FDA has taken action against sellers. Personal importation is generally not permitted.
Does this site prescribe or sell peptides?
No. Peptide Wellness Partners is an educational website. It does not provide medical advice, prescriptions, or products. Treatment decisions belong to a licensed clinician.
Is this an AI-operated clinic?
No. Software may help with education, navigation, and (later) support or intake routing. It cannot legally examine you, prescribe, or replace a licensed professional.
Do you have doctors on staff?
Peptide Wellness Partners does not hold itself out as a medical practice. If a telehealth partner is configured, you leave this site and continue with that partner’s licensed clinicians. Until a partner URL is set, provider access is not live — you can join the waitlist or use the public license lookups.
How current is this information?
Regulatory status can change. Check FDA.gov, the Federal Register, and your state boards. This resource reflects publicly available information as of November 2026.
Privacy policy
Stub — have counsel review before launch
This is a draft privacy notice for the static educational site. It is not a final legal policy.
What we intend to collect
- Waitlist name and email, if you submit the form, plus the time and that the source was this site.
- Peptides you choose to save, stored in your browser via localStorage when the browser allows it.
- Basic technical logs if a host or form provider is later connected (for example, IP address or browser type collected by that provider).
What we do not collect on this page
This site is not designed to collect medical histories, lab results, or other health information. Do not submit health details in the waitlist form. If a telehealth partner is connected, their intake and privacy practices apply once you leave this site.
Use and sharing
Waitlist details should be used only to notify you about Peptide Wellness Partners updates you asked for. They should not be sold. If a configured waitlist endpoint or analytics tool is added, that provider will process the data under its terms. A future business associate or vendor list should be added here after counsel review.
Your choices
You can stop using the site, clear site data in your browser, and (once email sending is configured) unsubscribe from waitlist messages. Depending on your state, additional privacy rights may apply.
Contact
A public contact email has not been configured yet.
Terms of use
Stub — have counsel review before launch
These draft terms describe how this educational website is meant to be used. They are not a finished contract and are not legal advice.
- The site is an educational resource about U.S. pathways for peptide medicines. It does not create a clinician–patient relationship.
- Information may be incomplete or outdated. You are responsible for checking official sources and licensed professionals.
- You may not use this site to obtain or offer unapproved drugs, to solicit prescriptions without a lawful evaluation, or to misrepresent licenses.
- Links to government sites, boards, or a configured telehealth partner are for convenience. Those third parties have their own terms.
- Membership prices and checkout shown on this site are placeholders until they are expressly activated.
- The site is provided as-is. Limitation of liability, dispute resolution, and governing law should be completed by counsel (a Texas governing-law clause may be appropriate if the operator is based there).